Cargando…
Beta-2 Adrenergic Receptor Agonists Enhance AChR Clustering in C2C12 Myotubes: Implications for Therapy of Myasthenic Disorders
BACKGROUND: Congenital myasthenic syndromes (CMS) are a group of inherited neuromuscular transmission disorders causing fatiguable muscle weakness. ADRB2 agonists have been observed to provide therapeutic benefit where destabilisation of NMJ structures is part of the underlying pathology, such as in...
Autores principales: | Clausen, Lisa, Cossins, Judith, Beeson, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004912/ https://www.ncbi.nlm.nih.gov/pubmed/29865088 http://dx.doi.org/10.3233/JND-170293 |
Ejemplares similares
-
Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs
por: Cetin, Hakan, et al.
Publicado: (2020) -
Selective cleavage of AChR cRNAs harbouring mutations underlying the slow channel myasthenic syndrome by hammerhead ribozymes
por: Abdelgany, Amr, et al.
Publicado: (2005) -
IgG1-3 MuSK Antibodies Inhibit AChR Cluster Formation, Restored by SHP2 Inhibitor, Despite Normal MuSK, DOK7, or AChR Subunit Phosphorylation
por: Cao, Michelangelo, et al.
Publicado: (2023) -
SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody
por: Huda, Saif, et al.
Publicado: (2019) -
Agrin-induced reorganization of extracellular matrix components on cultured myotubes: relationship to AChR aggregation
Publicado: (1990)